Back to Search Start Over

NCCN GuidelinesĀ® Insights: Prostate Cancer, Version 1.2023.

Authors :
Schaeffer EM
Srinivas S
Adra N
An Y
Barocas D
Bitting R
Bryce A
Chapin B
Cheng HH
D'Amico AV
Desai N
Dorff T
Eastham JA
Farrington TA
Gao X
Gupta S
Guzzo T
Ippolito JE
Kuettel MR
Lang JM
Lotan T
McKay RR
Morgan T
Netto G
Pow-Sang JM
Reiter R
Roach M
Robin T
Rosenfeld S
Shabsigh A
Spratt D
Teply BA
Tward J
Valicenti R
Wong JK
Berardi RA
Shead DA
Freedman-Cass DA
Source :
Journal of the National Comprehensive Cancer Network : JNCCN [J Natl Compr Canc Netw] 2022 Dec; Vol. 20 (12), pp. 1288-1298.
Publication Year :
2022

Abstract

The NCCN Guidelines for Prostate Cancer address staging and risk assessment after a prostate cancer diagnosis and include management options for localized, regional, recurrent, and metastatic disease. The NCCN Prostate Cancer Panel meets annually to reevaluate and update their recommendations based on new clinical data and input from within NCCN Member Institutions and from external entities. These NCCN Guidelines Insights summarizes much of the panel's discussions for the 4.2022 and 1.2023 updates to the guidelines regarding systemic therapy for metastatic prostate cancer.

Details

Language :
English
ISSN :
1540-1413
Volume :
20
Issue :
12
Database :
MEDLINE
Journal :
Journal of the National Comprehensive Cancer Network : JNCCN
Publication Type :
Academic Journal
Accession number :
36509074
Full Text :
https://doi.org/10.6004/jnccn.2022.0063